

Oregon Bioscience Association

Oregon's 2025 Portland Metro Economic Impact Snapshot

Measuring the Economic, Fiscal and Demographic Impacts of Oregon's Life and Bioscience Industry including Clark County, Washington.

BIOSCIENCE IN PORTLAND METRO

889 Firms

10,578 Employees

$1.1B Total Annual Wages

BIOSCIENCE DIRECT IMPACTS IN PORTLAND METRO, BY SECTOR, 2023

Clackamas, Multnomah, Washington Counties

Portland Metro	Count of Establishment	Sum of Average Annual Employment	Sum of Total Annual Wages
Agricultural Feedstock & Chemicals Manufacturing	7	48	$2.7M
Bioscience-related Distribution	313	2,969	$404.6M
Drugs & Pharmaceuticals	46	605	$43.8M
Medical Devices & Equipment	89	2,888	$255.6M
Research, Testing, & Medical Laboratories	434	4,068	$402.1M
Grand Total	889	10,578	$1.1B

NIH FUNDING PORTLAND METRO



$12M in SBIR/STTR funding was awarded to 14 Portland Metro area organizations in 2023

Bioscience Total Impacts Statewide

Every 10 jobs in the bioscience industry is linked to an additional 17 jobs
Every $1 million in income directly generated in the bioscience industry is linked to another $1 million in income

$21.2B Total Economic Output

$5.6B in Exports

$416.8M Funding from the NIH

$6.8B Total Labor Income

74,925 Total Jobs Supported

For full report visit www.oregonbio.org/reports

COMPANY SPOTLIGHTS

Araceli Biosciences

Tigard-based Araceli Biosciences is revolutionizing drug discovery with its Araceli Endeavor® imaging platform, the fastest high-content imaging system available. The platform reduces imaging time from hours to minutes, accelerating breakthroughs in small molecule and biologics discovery. Committed to local innovation, Araceli partners with Oregon-based companies and institutions, offering internships and job opportunities that support the state's growing bioscience sector. By combining speed, precision, and cutting-edge technology, Araceli strengthens Oregon's role as a leader in the life sciences industry.

Genentech

Founded in 1976, Genentech pioneered the biotech industry, introducing transformative medicines such as the first targeted antibody for cancer. Today, as a member of the Roche Group, Genentech continues its mission to improve global health through breakthrough therapies and innovations in cell and gene therapy. The company's commitment to Oregon began in 2006 with the Hillsboro Technical Operations (HTO) facility, which handles the filling, packaging, and distribution of medicines worldwide. In 2021, the Hillsboro Innovative Therapies (HIT) facility was added, focusing on cutting-edge personalized therapies. Together, these facilities represent a $650 million investment, employing over 900 Oregonians. Genentech also supports STEM education and workforce development, reinforcing Oregon's bioscience ecosystem.

MSEI (Micro Systems Engineering, Inc.)

For over 40 years, Lake Oswego-based MSEI has been a pioneer in medical microelectronics, specializing in active implants like pacemakers and cardiac rhythm management devices. MSEI combines advanced system design with precision manufacturing, all conducted in Oregon to ensure unparalleled quality and reliability. The company's highly skilled team of over 400 engineers and scientists drive breakthroughs in healthcare, offering application-specific integrated circuits (ASICs) and custom hardware solutions. MSEI is deeply rooted in Oregon's bioscience ecosystem, contributing to life-saving medical advancements and strengthening the local economy through high-tech innovation and sustainable growth.

THANK YOU TO OUR UNDERWRITING PARTNER: business oregon

Aronora

Aronora, an Oregon Health & Science University (OHSU) spinout, develops innovative therapies for blood clotting disorders without the bleeding risks of current treatments. With three drug candidates in clinical trials and over $60 million raised, Aronora is a leader in its field. Since establishing its Portland office and labs, supported by an SBIR matching grant, the company has become a key contributor to Oregon's bioscience ecosystem. CEO Dr. Erik Tucker credits strong local collaborations for Aronora's success, which reflects the dynamic growth of the state's biomedical innovation sector.

Keliomics

Portland-based Keliomics is transforming breast cancer therapeutic development with its proprietary NExTissue platform, combining AI and a 3D tissue model to accelerate drug discovery. This innovative approach enhances the translatability of new therapies while reducing reliance on traditional animal testing. In 2024, Keliomics received a Phase I SBIR grant from the National Cancer Institute to advance treatments for estrogen-receptor-positive breast cancer, which disproportionately affects Black women and other underserved groups. Supported by local and federal programs, Keliomics is dedicated to developing inclusive, next-generation cancer therapeutics that improve outcomes worldwide.

Twist Bioscience

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, by using our synthetic DNA and next-generation sequencing tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform and NGS Sequencing Offering provide precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. In fiscal 2024, we reported $313 million in revenue, growth of 28% over fiscal 2023. We manufacture several products in our Wilsonville, OR facility.